Adverse events

Study	Description	Exenatide 2 mg QW	Insulin glargine
E ‐ Diamant 2010	withdrawal due to adverse events	11 (4.7%)	2 (0.9%)
E ‐ Diamant 2010	nausea	30 (13%)	3 (1%)
E ‐ Diamant 2010	vomiting	10 (4%)	3 (1%)
E ‐ Diamant 2010	diarrhoea	20 (9%)	8 (4%)
E ‐ Diamant 2010	Nasopharyngitis	30 (13%)	39 (17%)
E ‐ Diamant 2010	Headache	23 (10%)	16 (7%)
E ‐ Diamant 2010	Injection‐site reaction	30 (13%)	4 (2%)
E ‐ Diamant 2010	Patients with one or more serious adverse events Pancreatitis	11 (5%) 1 (0.4%)	10 (4%) None
E ‐ Diamant 2010	Deaths	None	None
E ‐ Diamant 2010	Anti‐exenatide antibodies	127/233 (54.5%) tested positive for anti‐exenatide antibodies. No effect on HbA1c	‐